Gene-expression-based Prognostic Assays for Breast Cancer

Overview

Journal Nat Rev Clin Oncol

Specialty Oncology

Date 2010 May 5

PMID 20440284

Citations 55

Authors

Chungyeul Kim

Soonmyung Paik

Affiliations

Soon will be listed here.

Abstract

Several gene-expression-based reference laboratory tests are now available for prognostication of patients diagnosed with breast cancer. For clinical oncologists, it is important to understand the clinical contexts for which these assays were developed in order to use them properly. This Review is aimed at providing a conceptual and technical overview of the steps involved in the development of gene-expression profiling-based prognostic assays. MammaPrint and Oncotype DX, two widely utilized assays, are compared with respect to differences in the clinical contexts for their development, technologies used, and clinical utilities with the aim of providing a guide to clinical oncologists for utilization of these assays.

Citing Articles

AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.

Sardar S, McNair C, Ravindranath L, Chand S, Yuan W, Bogdan D Oncogene. 2024; 43(43):3197-3213.

PMID: 39266679 PMC: 11493679. DOI: 10.1038/s41388-024-03148-4.

AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.

Sardar S, McNair C, Ravindranath L, Chand S, Yuan W, Bogdan D bioRxiv. 2024; .

PMID: 38766099 PMC: 11100730. DOI: 10.1101/2024.05.07.592966.

Association of serum cortisol and cortisone levels and risk of recurrence after endocrine treatment in breast cancer.

Wang F, Giskeodegard G, Skarra S, Engstrom M, Hagen L, Geisler J Clin Exp Med. 2023; 23(7):3883-3893.

PMID: 37395895 PMC: 10618334. DOI: 10.1007/s10238-023-01109-x.

Reproducibility and intratumoral heterogeneity of the PAM50 breast cancer assay.

Hurson A, Hamilton A, Olsson L, Kirk E, Sherman M, Calhoun B Breast Cancer Res Treat. 2023; 199(1):147-154.

PMID: 36892725 PMC: 10147733. DOI: 10.1007/s10549-023-06888-1.

Diagnosis of childhood and adolescent growth hormone deficiency using transcriptomic data.

Garner T, Wangsaputra I, Whatmore A, Clayton P, Stevens A, Murray P Front Endocrinol (Lausanne). 2023; 14:1026187.

PMID: 36864831 PMC: 9973753. DOI: 10.3389/fendo.2023.1026187.

References

Glas A, Floore A, Delahaye L, Witteveen A, Pover R, Bakx N . Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics. 2006; 7:278. PMC: 1636049. DOI: 10.1186/1471-2164-7-278. View

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

Cardoso F, Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart M . Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol. 2008; 26(5):729-35. DOI: 10.1200/JCO.2007.14.3222. View

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W . Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006; 24(23):3726-34. DOI: 10.1200/JCO.2005.04.7985. View

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

Schardt J, Meyer M, Hartmann C, Schubert F, Schmidt-Kittler O, Fuhrmann C . Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell. 2005; 8(3):227-39. DOI: 10.1016/j.ccr.2005.08.003. View

Paik S, Kim C, Song Y, Kim W . Technology insight: Application of molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer. Nat Clin Pract Oncol. 2005; 2(5):246-54. DOI: 10.1038/ncponc0171. View

Schena M, Shalon D, Davis R, Brown P . Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995; 270(5235):467-70. DOI: 10.1126/science.270.5235.467. View

Parker J, Mullins M, Cheang M, Leung S, Voduc D, Vickery T . Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009; 27(8):1160-7. PMC: 2667820. DOI: 10.1200/JCO.2008.18.1370. View

10.

Sorlie T, Perou C, Tibshirani R, Aas T, Geisler S, Johnsen H . Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98(19):10869-74. PMC: 58566. DOI: 10.1073/pnas.191367098. View

11.

Toussaint J, Sieuwerts A, Haibe-Kains B, Desmedt C, Rouas G, Harris A . Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues. BMC Genomics. 2009; 10:424. PMC: 2756282. DOI: 10.1186/1471-2164-10-424. View

12.

Mook S, Schmidt M, Weigelt B, Kreike B, Eekhout I, van de Vijver M . The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol. 2009; 21(4):717-722. DOI: 10.1093/annonc/mdp388. View

13.

Wittner B, Sgroi D, Ryan P, Bruinsma T, Glas A, Male A . Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin Cancer Res. 2008; 14(10):2988-93. PMC: 3089800. DOI: 10.1158/1078-0432.CCR-07-4723. View

14.

Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J . Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006; 98(4):262-72. DOI: 10.1093/jnci/djj052. View

15.

Fan C, Oh D, Wessels L, Weigelt B, Nuyten D, Nobel A . Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006; 355(6):560-9. DOI: 10.1056/NEJMoa052933. View

16.

Kim C, Taniyama Y, Paik S . Gene expression-based prognostic and predictive markers for breast cancer: a primer for practicing pathologists. Arch Pathol Lab Med. 2009; 133(6):855-9. PMC: 2692069. DOI: 10.5858/133.6.855. View

17.

Cardoso F, Piccart-Gebhart M, Veer L, Rutgers E . The MINDACT trial: the first prospective clinical validation of a genomic tool. Mol Oncol. 2009; 1(3):246-51. PMC: 5543876. DOI: 10.1016/j.molonc.2007.10.004. View

18.

J van t Veer L, Dai H, van de Vijver M, He Y, Hart A, Mao M . Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415(6871):530-6. DOI: 10.1038/415530a. View

19.

Habel L, Shak S, Jacobs M, Capra A, Alexander C, Pho M . A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 2006; 8(3):R25. PMC: 1557737. DOI: 10.1186/bcr1412. View

20.

Sparano J . TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer. 2006; 7(4):347-50. DOI: 10.3816/CBC.2006.n.051. View